Home / Products / Antibiotics / CIXUP-OL
Click image to inspect pack details
Antibiotics Marketed by Aerochem Neutron

CIXUP-OL

Formulation Code AC-479
Commercial Status Active Product Information Available

Product Overview & Formulation Profile

Description

Cefixime 200 mg + Ofloxacin 200 mg Tablets

This fixed-dose combination contains cefixime, a third-generation cephalosporin antibiotic, and ofloxacin, a fluoroquinolone antibacterial agent.

Cefixime inhibits bacterial cell-wall synthesis by binding to penicillin-binding proteins. Ofloxacin acts on bacterial DNA gyrase and topoisomerase IV, enzymes involved in bacterial DNA replication.

The two components act through different antibacterial mechanisms. However, their combination does not automatically establish superior efficacy, broader clinical utility or improved outcomes compared with appropriate single-agent treatment.

The clinical justification for using both agents together must be established for the specific infection and supported by the product's Indian marketing authorisation, available evidence and relevant treatment guidelines.

Composition: Cefixime 200 mg + Ofloxacin 200 mg
Dosage Form: Tablets
Packing: 10 x 10 Alu Alu

Prescription medicine. Use only under the supervision of a registered medical practitioner.

Composition & Formulation Details

Features

  • Dual antibacterial composition: Contains cefixime 200 mg and ofloxacin 200 mg.

  • Cephalosporin component: Cefixime inhibits bacterial cell-wall synthesis.

  • Fluoroquinolone component: Ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV.

  • Different mechanisms of action: The ingredients act on distinct bacterial targets; a clinical advantage from combining them must not be presumed.

  • Clinical considerations: Use requires an authorised indication, appropriate patient selection and consideration of antimicrobial susceptibility and safety.

Conditions

  • Typhoid Fever: Treatment of typhoid fever in adults, where clinically appropriate and supported by bacterial susceptibility.

  • Urinary Tract Infections (UTIs): Treatment of susceptible bacterial urinary tract infections in adults, subject to appropriate antibiotic selection.

Use should be guided by clinical assessment, culture and susceptibility findings where appropriate, local antimicrobial resistance patterns, and the approved prescribing information.

For use only under the supervision of a registered medical practitioner.

Professional Product Enquiries

Verified product information, formulation specifications, and commercial supply pathways for registered healthcare professionals, institutions, and trade partners.

Product Information

Review verified active composition, strength, dosage form, and packaging details on this page.

View Specifications

Healthcare Professional Enquiry

Request formulation literature, technical specifications, or product communication from our commercial team.

Submit Product Enquiry

Commercial Supply Enquiry

Connect regarding institutional supply requirements, trade distribution, or third-party contract manufacturing.

Commercial Enquiry

Professional Product Information

This product information is intended for registered healthcare professionals, medical practitioners, and authorized distribution partners. Product manufacturing is coordinated through eligible facility partners under applicable licences.

Product Enquiry

Request Formulation Details

Request information about CIXUP-OL for professional use.

Please enter the numeric sum to verify you are a human visitor.
Therapeutic Alternatives

Related Formulations

SULTAVIN Formulation
AEROCLAV -625 Formulation
AEROFLOX 200 Formulation
A.G 250 Formulation
Product Information

Need specifications for this formulation?

Request verified product information for professional use, or send a separate business enquiry for manufacturing or partnership discussions.

WhatsApp: +91 9512047000